Drug treatment of hypertension in pregnancy: A critical review of adult guideline recommendations

Journal of Hypertension

Volumn 32, Issue 3, 2014, Pages 454-463

  Al Khaja, Khalid A J ^a   Sequeira, Reginald P ^a   Alkhaja, Alwaleed K ^b   Damanhori, Awatif H H ^c  

^a ARABIAN GULF UNIVERSITY   (Bahrain)

^b QATAR FOUNDATION   (Qatar)

^c Primary Care   (Bahrain)

Author keywords

Antihypertensive drugs; Guidelines evaluation; Hypertension; Hypertensive crisis; Pregnancy; Treatment guidelines

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLOROTHIAZIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCERYL TRINITRATE; HYDRALAZINE; LABETALOL; MAGNESIUM SULFATE; METHYLDOPA; METOPROLOL; NIFEDIPINE; NITROPRUSSIDE SODIUM; OXPRENOLOL;

APGAR SCORE; BRADYCARDIA; CESAREAN SECTION; CLINICAL TRIAL (TOPIC); CONGENITAL MALFORMATION; CYANIDE POISONING; DIGESTIVE SYSTEM DISEASE; DRUG CONTRAINDICATION; DRUG SAFETY; ECLAMPSIA; ELECTROLYTE DISTURBANCE; EVALUATION STUDY; FETUS DEATH; FETUS DISEASE; FETUS DISTRESS; FETUS HEART; FETUS HYPOXIA; FETUS OUTCOME; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOCALCEMIA; HYPOGLYCEMIA; HYPOTENSION; JAUNDICE; KIDNEY FAILURE; LOW BIRTH WEIGHT; LUNG EDEMA; NEONATAL THROMBOCYTOPENIA; OLIGURIA; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY DISTRESS SYNDROME; REVIEW; RISK REDUCTION; SMALL FOR DATE INFANT; SOLUTIO PLACENTAE; SPONTANEOUS ABORTION; TACHYCARDIA; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIURETICS; FEMALE; FETUS; HUMANS; HYPERTENSION; METHYLDOPA; OUTCOME ASSESSMENT (HEALTH CARE); PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR;

EID: 84894053131     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000069     Document Type: Review

References (71)

1. Sibai BM. Treatment of hypertension in pregnant women. N Engl J Med 1996; 335:257-265.
2. Sibai BM. Antihypertensive drugs during pregnancy. Semin Perinatol 2001; 25:159-164.
3. Allen VM. The effect of hypertensive disorders in pregnancy on perinatal outcomes: a population-based cohort study. Ottawa: National Library of Canada; 2002.
4. Magee LA, Helewa M, Moutkin JM, von Dadelszen P. Hypertension Guideline Committee, and Strategic Training Initiative in Research in the Reproductive Health Sciences (STIRRHS) Scholars. Diagnosis, Evaluation, and Management of the Hypertensive Disorders of Pregnancy. JOGC 2008; 30 (Suppl 1):S1-S52.
5. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 - Complete report. Hypertension 2003; 42:1206-1252.
6. Podynow T, August P. Update on the use of antihypertensive drugs in pregnancy. Hypertension 2008; 51:960-969.
7. Alderman MH, Furberg CD, Kostis JB, Laragh JH, Psaty BM, Ruilope LM, et al. Hypertension guidelines: criteria that might make them more useful. Am J Hypertens 2002; 15:917-923.
8. Lenfant C. Reflection on hypertension control rates. A message from the director of the National Heart, Lung and Blood Institute. Arch Intern Med 2002; 162:131-132.
9. National Institute of Health and Clinical Excellence. Hypertension in pregnancy. The management of hypertension disorders during pregnancy. Clinical Guidelines CG107. Issued August 2010 (revised reprint January 2011). http://www.nice.org.uk/nicemedia/live/13098/50475/50475.pdf. [Accessed March 2013].
10. Khatib OMN, El-Guindy MS. Clinical guidelines for the management of hypertension. World Health Organization, Regional Office for Eastern Mediterranean, EMRO Technical Publication Series 29; 2005. http://applications. emro.who.int/dsaf/dsa234.pdf. [Accessed March 2013].
11. Seedat YK, Rayner BL. South African Hypertension Guidelines 2011. S Afr Med J 2011; 102:57-84.
12. Gulf Heart Association (GHA). Guidelines for the management of arterial hypertension. Pocket Guidelines; 2010. http://www.gulf heart.org/admin/editor/ jscripts/uploads/GHA Hypertension04.pdf [Accessed March 2013].
13. Guidelines for the management of hypertension in primary care settings and outpatient clinics in the Kingdom of Bahrain, 2008.
14. Clinical Practice Guidelines: Management of hypertension (3rd edition) MOH/P/PAK/156.08 (GU), 2008, Ministry of Health, Malaysia. http://xa.yimg.com/ kq/groups/2095389/1906139185/name/CPG Hypertension3rdEdition2008QuickReference. pdf. [Accessed December 2013].
15. Clinical Practice Guidelines: Hypertension: MOH clinical practice guidelines 2/2005, Ministry of Health, Singapore. http://www.moh. gov.sg/content/dam/mohweb/HPP/Doctors/cpg-medical/withdrawn/cpg-Hypertension- Jun%202005.pdf [Accessed March 2013].
16. Saudi Hypertension Management society. Saudi Hypertension Management Society Guidelines 2011. http://www.saudihtn.org/upload/1302965700.pdf. [Accessed March 2013].
17. Chiang CE, Wang TD, Li YH, Lin TH, Chien KL, Yeh HI, et al. 2010 Guidelines of the Taiwan Society of Cardiology for the management of hypertension. J Formos Med Assoc 2010; 109:740-773.
18. Park JB. 2004 Korean hypertension treatment guidelines and its perspective. Korean Circ J 2006; 36:405-410.
19. Hong Kong reference framework for hypertension care for adults in primary care settings 2010. http://www.fhb.gov.hk/download/press-and-publications/ otherinfo/101231-primary- care/e-hypertension- care.pdf. [Accessed March 2013].
20. Heart Foundation. Guide to management of hypertension 2008. Assessing and managing raised blood pressure in adults. Updated December 2010. http://www.heartfoundation.org.au/SiteCollection Documents/ HypertensionGuidelines2008to2010Update.pdf. [Accessed March 2013].
21. Sanchez RA, Ayala M, Baglivo H, Velazquez C, Burlando G, Kohlmann O, et al. Latin American Guidelines on Hypertension. Latin American Expert Group. J Hypertens 2009; 27:905-922.
22. Pan American Health Organization. Managing hypertension in primary care in the Caribbean; 2007. http://www.chrc-caribbean.org/Portals/0/Downloads/ Publications/Clinical%20Guidelines/Hypertension.pdf. [Accessed March 2013].
23. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al. BHS Guidelines Working Party, for the British Hypertension Society. Guidelines for management of hypertension: report of the fourth Working Party of the British Hypertension Society, - BHS IV. J Hum Hypertens 2004; 18:139-185.
24. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH /ESC Guidelines for the management of arterial hypertension. The Task for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). J Hypertens 2013; 31:1281-1357.
25. National Institute for Health and Clinical Excellence (NICE). Hypertension. The clinical management of primary hypertension in adults. Clinical Guideline 127. Methods, evidence and recommendation, August 2011. http://publications.nice.org.uk/hypertension-cg127/guidance [Accessed March 2013].
26. Scottish Intercollegiate Guidelines Network (SIGN). Risk estimation and the prevention of cardiovascular disease. A national clinical guideline. February 2007. http://www.sign.ac.uk/pdf/sign97.pdf. [Accessed March 2013].
27. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21:1983-1992.
28. 2007 World Health Organization (WHO). Prevention of cardiovascular diseases. Guidelines for assessment and management of cardiovascular risk 2007. http://www.who.int/cardiovascular-diseases/guidelines/PocketGL.ENGLISH.AFR-D-E. rev1.pdf. [Accessed December 2013].
29. AACE Hypertension Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of hypertension. Endocr Pract 2006; 12:193-222.
30. Rabi DM, Daskalopoulou SS, Padwal RS, Khan NA, Grover SA, Hackam DG, et al. The 2011 Canadian Hypertension Education Program Recommendation for the Management of Hypertension: blood pressure treatment, diagnosis, assessment of risk and therapy. Can J Cardiol 2011; 27:415-433.
31. Department of Veteran Administration/Department of Defense (VA/DoD) clinical practice guidelines for diagnosis and management of hypertension in the primary care setting. Department of Veteran Administration/Department of Defense. Update version 2.ob.2004. http://www.healthquality.va.gov/hypertension/ htn04-pdf1.pdf. [Accessed December 2013].
32. Institute for Clinical Systems Improvement (ICSI) Healthcare Guidelines. Hypertension, diagnosis and treatment. 13th ed. November 2010. https://www.icsi.org/-asset/wjqy4g/HTN.pdf [Accessed March 2013].
33. Nursing Best PracticeGuidelines.Nursing management of hypertension. Registered Nurses' Association of Ontario, October 2005. http://rnao.ca/bpg/ guidelines/nursing-management-hypertension. [Accessed March 2013].
34. Fidler J, Smith V, Fayers P, De Swiet M. Randomized controlled comparative study of methyldopa and oxprenolol in treatment of hypertension in pregnancy. BMJ 1983; 286:1927-1930.
35. Cockburn J, Moar VA, Ounsted M, Redman CW. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet 1982; 1:647-649.
36. Montan S, Anandakumar C, Arulkumaran S, Ingemarsson I, Ratnam SS. Effects of methyldopa on uteroplacental and fetal hemodynamics in pregnancy-induced hypertension. Am J Obstet Gynecol 1993; 168:152-156.
37. Kyle PM, Redman CW. Comparative risk-benefit assessment of drugs used in the management of hypertension in pregnancy. Drug Saf 1992; 7:223-234.
38. Puzey MS, Ackovic KL, Lindow SW, Gonin R. The effect of nifedipine on fetal umbilical artery Doppler waveforms in pregnancy complicated by hypertension. S Afr Med J 1991; 79:192-194.
39. Wide-Swensson DH, Ingemarsson I, Lunell NO, Foman A, Skajaa K, Lindberg B, et al. Calcium channel blockade (Isradipine) in treatment of hypertension in pregnancy: a randomized placebo-controlled study. Am J Obstet Gynecol 1995; 173:872-878.
40. Casele HL, Windley KC, Prieto JA, Gratton R, Laifer SA. Felodipine use in pregnancy. Report of three cases. J Reprod Med 1997; 42:378-381.
41. Jannet D, Carbonne B, Sebban E, Milliez J. Nicardipine versus metoprolol in the treatment of hypertension during pregnancy: a randomized comparative trial. Obstet Gynecol 1994; 84:354-359.
42. Belfort MA, Anthony J, Buccimazza A, Davey DA. Hemodynamic changes associated with intravenous infusion of the calcium channel antagonist verapamil in the treatment of severe gestational proteinuric hypertension. Obstet Gynecol 1990; 75:970-974.
43. Impey I. Severe hypotension and fetal distress following sublingual administration of nifedipine to a patient with severe pregnancy induced hypertension at 33 weeks. Br J Obstet Gynaecol 1993; 100:959-961.
44. Brown MA, Buddle ML, Farrell T, Davis GK. Efficacy and safety of nifedipine tablets for the acute treatment of severe hypertension in pregnancy. Am J Obstet Gynecol 2002; 187:1046-1056.
45. Butters L, Kennedy S, Rubin PC. Atenolol in essential hypertension during pregnancy. BMJ 1990; 301:587-589.
46. Lip G, Beevers M, Churchill D, Shaffer LM, Beevers DR. Effect of atenolol on birth weight. Am J Cardiol 1997; 79:1436-1438.
47. Nakhai-Pour HR, Rey E, Berard A. Antihypertensive medication use during pregnancy and the risk of major congenital malformations or small-for- gestational-age newborns. Birth Defects Res B Dev Reprod Toxicol 2010; 89:147-154.
48. Magee LA, Elran E, Bull SB, Logan A, Koren G. Risks and benefits of beta-receptor blockers for pregnancy hypertension: overview of the randomized trials. Eur J Obstet Gynecol Reprod Biol 2000; 88:15-26.
49. Davis RL, Eastman D, McPhillips H, Raebel MA, Andrade SE, Smith D, et al. Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. Pharmacoepidemiol Drug Saf 2011; 20:138-145.
50. Langdon D, Stanley C. Pediatric endocrinology. In: Sperling MA, editor. Hypoglycemia in the infant and child. Amsterdam: Elsevier Health Sciences; 2008. p. 889.
51. Gallery EDM, Ross MR, Gyory AZ. Antihypertensive treatment in pregnancy: analysis of different responses to oxprenolol and methyldopa. BMJ 1985; 291:563-566.
52. Sibai BM, Grossman RA, Grossman HG. Effects of diuretics on plasma volume in pregnancies with long-term hypertension. Am J Obstet Gynecol 1984; 150:831-835.
53. Moser M, Brown CM, Rose CH, Garovic VD. Hypertension in pregnancy: is it time for a new approach to treatment? J Hypertens 2012; 30:1092-1100.
54. Buttar HS. An overview of the reference of ACE inhibitors on fetalplacental circulation and perinatal development. Mol Cell Biochem 1997; 176:61-71.
55. Alwan S, Polifka JE, Friedman JM. Angiotensin II receptor antagonist treatment during pregnancy. Birth Defects Res A Clin Mol Teratol 2005; 73:123-130.
56. Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Eng J Med 2006; 354:2443-2451.
57. Moretti ME, Caprara D, Drehuta I, Yeung E, Cheung S, Federico L, et al. The fetal safety of angiotensin converting enzyme inhibitors and angiiotensin II receptor blockers. Obstet Gynecol Int 2012; 2012: 658310. doi: 10.1155/2012/658310.
58. Duley L, Henderson-Smart DJ, Meher S. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev 2006;CD001449. doi: http://dx.doi.org/10.1002/14651858.CD001449. pub2.
59. Vigil-De Gracia P, Lasso M, Ruiz E, Vega-Malek JC, de Mena FT, Lopez JC, et al. Severe hypertension in pregnancy: hydralazine or labetalol. A randomized clinical trial. Eur J Obstet Gynecol Reprod Biol 2006; 128:157-162.
60. Baggio MR, Martin WP, Calderon AC, Berezowski AT, Marcolin AC, Duarte G, et al. Changes in fetal and maternal Doppler parameter observed during acute severe hypertension treatment with hydralazine or labetalol: a randomized control trial. Ultrasound Med Biol 2011; 37:53-58.
61. Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ 2003; 327:955-960.
62. Magee LA, von Dadelszen P, Chan S, Gafni A, Gruslin A, Helewa M, et al. The control of hypertension in pregnancy study pilot study. BJOG 2007; 770:e13-e20.
63. Society of Obstetricians and Gynecologists of Canada (SOGC). SOGC Clinical Practice Guidelines. Diagnosis, Evaluation, and Management of the Hypertensive Disorders of Pregnancy. JOGC 2008; 30 (suppl.1): S1-S49.
64. Society of Obstetric Medicine of Australia and New Zealand (SOMANZ). Guidelines for the Management of Hypertensive disorders of Pregnancy 2008. http://www.somanz.org/pdfs/somanz-guide lines-2008.pdf. [Accessed March 2013].
65. The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). ESC Guidelines on the management of cardiovascular diseases during pregnancy. Eur Heart J 2011; 32:3147-3197.
66. Waisman GD, Mayorga LM, Camera MI, Vignolo CA, Martinotti A. Magnesium plus nifedipine: potentiation of hypotensive effect in preeclampsia? Am J Obstet Gynecol 1988; 159:308-309.
67. Koontz SL, Friedman SA, Schwartz ML. Symptomatic hypocalcemia after tocolytic therapy with magnesium sulfate and nifedipine. Am J Obstet Gynecol 2004; 190:1773-1776.
68. Magee LA, Miremadi S, Li J, Cheng C, Ensom MH, Carleton B, et al. Therapy with both magnesium sulphate and nifedipine does not increase the risk of serious magnesium-related maternal side effects in women with preeclampsia. Am J Obstet Gynecol 2005; 193:153-163.
69. National Center for Health Statistics: http://www.CDC.gov/nchs/nhcs.htm. [Accessed March 2013].
70. Martin U, Foreman MA, Travis JC, Casson D, Coleman JJ. Use of ACE inhibitors and ARBs in hypertensive women of childbearing age. J Clin Pharm Ther 2008; 33:507-511.
71. Sorof JM, Lai D, Turner J, Poffenbarger T, Portman RJ. Overweight, ethnicity, and the prevalence of hypertension in school-aged children. Pediatrics 2004; 113:475-482.